[1]
|
李宜臻, 郑怡, 邓玉皎, 等. 1990~2019中国女性乳腺癌疾病负担及危险因素研究[J]. 中国循证医学杂志, 2021, 21(8): 876-881.
|
[2]
|
赫捷, 陈万青, 李霓, 等. 中国女性乳腺癌筛查与早诊早治指南(2021, 北京) [J]. 中国肿瘤, 2021, 30(3): 161-191.
|
[3]
|
Lee, K., Kruper, L., Dieli-Conwright, C.M. and Mortimer, J.E. (2019) The Impact of Obesity on Breast Cancer Diagnosis and Treatment. Current Oncology Reports, 21, Article No. 41. https://doi.org/10.1007/s11912-019-0787-1
|
[4]
|
de la Mare, J.A., Contu, L., Hunter, M.C., et al. (2014) Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment. Recent Patents on Anti-Cancer Drug Discovery, 9, 153-175.
https://doi.org/10.2174/15748928113086660046
|
[5]
|
Shien, T. and Iwata, H. (2020) Adjuvant and Neoadjuvant Therapy for Breast Cancer. Japanese Journal of Clinical Oncology, 50, 225-229. https://doi.org/10.1093/jjco/hyz213
|
[6]
|
Wang-Lopez, Q., Chalabi, N., Abrial, C., et al. (2015) Can Pathologic Complete Response (pCR) Be Used as a Surrogate Marker of Survival after Neoadjuvant Therapy for Breast Cancer? Critical Reviews in Oncology/Hematology, 95, 88-104.
|
[7]
|
Deepak, K.G.K., Vempati, R., Nagaraju, G.P., et al. (2020) Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. Pharmacological Research, 153, Article ID: 104683.
https://doi.org/10.1016/j.phrs.2020.104683
|
[8]
|
Park, S. and Yi, G. (2022) Development of Gene Expres-sion-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer. Cancers, 14, 881.
|
[9]
|
Salemme, V., Centonze, G., Cavallo, F., et al. (2021) The Crosstalk between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Frontiers in Oncology, 11, Article ID: 610303.
https://doi.org/10.3389/fonc.2021.610303
|
[10]
|
Lei, X., Lei, Y., Li, J.K., et al. (2020) Immune Cells within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy. Cancer Letters, 470, 126-133. https://doi.org/10.1016/j.canlet.2019.11.009
|
[11]
|
Savas, P., Caramia, F., Teo, Z.L. and Loi, S. (2014) Oncogene Addiction and Immunity: Clinical Implications of Tumour Infiltrating Lymphocytes in Breast Cancers Overexpressing the HER2/Neu Oncogene. Current Opinion in Oncology, 26, 562-567. https://doi.org/10.1097/CCO.0000000000000131
|
[12]
|
Dieci, M.V., Miglietta, F. and Guarneri, V. (2021) Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. Cells, 10, 223.
|
[13]
|
Gonzalez-Ericsson, P.I., Stovgaard, E.S., Sua, L.F., et al. (2020) The Path to a Better Biomarker: Application of a Risk Management Framework for the Implementation of PD-L1 and TILs as Immuno-Oncology Biomarkers in Breast Cancer Clinical Trials and Daily Practice. The Journal of Pathology, 250, 667-684. https://doi.org/10.1002/path.5406
|
[14]
|
Salgado, R., Denkert, C., Demaria, S., et al. (2015) The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology, 26, 259-271.
https://doi.org/10.1093/annonc/mdu450
|
[15]
|
Hendry, S., Salgado, R., Gevaert, T., et al. (2017) Assessing Tu-mor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointesti-nal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 24, 311-335.
https://doi.org/10.1097/PAP.0000000000000161
|
[16]
|
Romagnoli, G., Wiedermann, M., Hübner, F., et al. (2017) Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogen-icity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. International Journal of Mo-lecular Sciences, 18, Article No. 1936.
|
[17]
|
Jiang, X., Xu, J., Liu, M., et al. (2019) Adoptive CD8+ T Cell Therapy against Cancer: Challenges and Opportunities. Cancer Letters, 462, 23-32. https://doi.org/10.1016/j.canlet.2019.07.017
|
[18]
|
Schmidt, M., Weyer-Elberich, V., Hengstler, J.G., et al. (2018) Prognostic Impact of CD4-Positive T Cell Subsets in Early Breast Cancer: A Study Based on the FinHer Trial Patient Population. Breast Cancer Research, 20, Article No. 15. https://doi.org/10.1186/s13058-018-0942-x
|
[19]
|
Jensen, M.C. (2015) Immunology. Synthetic Immunobiology Boosts the IQ of T Cells. Science, 350, 514-515.
https://doi.org/10.1126/science.aad5289
|
[20]
|
Kobayashi, S., Watanabe, T., Suzuki, R., et al. (2016) TGF-β Induces the Differentiation of Human CXCL13-Producing CD4+ T Cells. European Journal of Immunology, 46, 360-371.
https://doi.org/10.1002/eji.201546043
|
[21]
|
Horii, M. and Matsushita, T. (2021) Regulatory B Cells and T Cell Regulation in Cancer. Journal of Molecular Biology, 433, Article ID: 166685. https://doi.org/10.1016/j.jmb.2020.10.019
|
[22]
|
Okada, M., Chikuma, S., Kondo, T., et al. (2017) Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. Cell Reports, 20, 1017-1028.
https://doi.org/10.1016/j.celrep.2017.07.027
|
[23]
|
Huang, M., O’Shaughnessy, J., Zhao, J., et al. (2020) Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network, 18, 1096-1104. https://doi.org/10.6004/jnccn.2020.7550
|
[24]
|
Xia, Y., Tao, H., Hu, Y., et al. (2016) IL-2 Augments the Therapeu-tic Efficacy of Adoptively Transferred B Cells Which Directly Kill Tumor Cells via the CXCR4/CXCL12 and Perforin Pathways. Oncotarget, 7, 60461-60474.
https://doi.org/10.18632/oncotarget.11124
|
[25]
|
Cabrita, R., Lauss, M., Sanna, A., et al. (2020) Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma. Nature, 577, 561-565. https://doi.org/10.1038/s41586-019-1914-8
|
[26]
|
Helmink, B.A., Reddy, S.M., Gao, J., et al. (2020) B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response. Nature, 577, 549-555. https://doi.org/10.1038/s41586-019-1922-8
|
[27]
|
Bell, D., Chomarat, P., Broyles, D., et al. (1999) In Breast Car-cinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peri-tumoral Areas. Journal of Experimental Medicine, 190, 1417-1426. https://doi.org/10.1084/jem.190.10.1417
|
[28]
|
Lee, H., Lee, H.J., Song, I.H., et al. (2018) CD11c-Positive Den-dritic Cells in Triple-Negative Breast Cancer. In Vivo, 32, 1561-1569. https://doi.org/10.21873/invivo.11415
|
[29]
|
Gardner, A., de Mingo Pulido, Á. and Ruffell, B. (2020) Dendritic Cells and Their Role in Immunotherapy. Frontiers in Immunology, 11, Article No. 924. https://doi.org/10.3389/fimmu.2020.00924
|
[30]
|
Nelson, M.A., Ngamcherdtrakul, W., Luoh, S.W. and Yantasee, W. (2021) Prognostic and Therapeutic Role of Tumor-Infiltrating Lymphocyte Subtypes in Breast Cancer. Cancer and Metastasis Reviews, 40, 519-536.
https://doi.org/10.1007/s10555-021-09968-0
|
[31]
|
Laenkholm, A.V., Callagy, G., Balancin, M., et al. (2022) In-corporation of TILs in Daily Breast Cancer Care: How Much Evidence Can We Bear? Virchows Archiv, 480, 147-162.
|
[32]
|
Denkert, C., Loibl, S., Noske, A., et al. (2010) Tumor-Associated Lymphocytes as an Independent Pre-dictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 28, 105-113.
https://doi.org/10.1200/JCO.2009.23.7370
|
[33]
|
Cortazar, P., Zhang, L., Untch, M., et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet, 384, 164-172.
https://doi.org/10.1016/S0140-6736(13)62422-8
|
[34]
|
Loi, S., Drubay, D., Adams, S., et al. (2019) Tu-mor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 37, 559-569.
https://doi.org/10.1200/JCO.18.01010
|
[35]
|
Stanton, S.E. and Disis, M.L. (2016) Clinical Significance of Tu-mor-Infiltrating Lymphocytes in Breast Cancer. Journal for ImmunoTherapy of Cancer, 4, Article No. 59. https://doi.org/10.1186/s40425-016-0165-6
|
[36]
|
Romero-Cordoba, S., Meneghini, E., Sant, M., et al. (2019) De-coding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. Can-cers, 11, 911.
|
[37]
|
Criscitiello, C., et al. (2020) Tumor-Infiltrating Lymphocytes (TILs) in ER+/HER2-Breast Cancer. Breast Cancer Research and Treatment, 183, 347-354. https://doi.org/10.1007/s10549-020-05771-7
|
[38]
|
Sobral-Leite, M., et al. (2019) Cancer-Immune Interactions in ER-Positive Breast Cancers: PI3K Pathway Alterations and Tumor-Infiltrating Lymphocytes. Breast Cancer Research, 21, Article No. 90.
https://doi.org/10.1186/s13058-019-1176-2
|
[39]
|
Pellegrino, B., Hlavata, Z., Migali, C., et al. (2021) Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis & Therapy, 25, 409-424. https://doi.org/10.1007/s40291-021-00525-7
|
[40]
|
Colombo, N., Sessa, C., du Bois, A., et al. (2019) ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease. Annals of Oncology, 30, 672-705. https://doi.org/10.1093/annonc/mdz062
|